Post-Scrip: The ASPL Pharmacy Law Podcast | S1E8 - Simone Colgan Dunlap, JD - Quarles & Brady LLP
Listen now
Description
In this episode, we welcome Simone Colgan Dunlap, JD with Quarles & Brady LLP. Simone gives our listeners a glimpse into her conference topic entitled: "Double, Double Toil and Trouble: Avoiding Regulatory Pitfalls Related to Thy Hubs Interactions." She also  shares how she got her beginnings in the industry.  This presentation will address key regulatory considerations implicated by pharmacy interactions with hubs--with a playful Shakespearian twist. If you have ever thought that hubs are greek to you, this presentation will give you the wings wherewith to fly confidently into the evolving world of hubs. Hubs play a unique role in the ecosystem of drug delivery and patient care and take on varied forms. As patient access strategies continue to evolve, all pharmacies should be prepared to navigate hub interactions. As the Bard said, “better three hours too soon, than a minute too late”! The 33rd annual American Society for Pharmacy Law Developments in Pharmacy Law seminar will be held November 3-6 at the Naples Grande Beach Resort in Naples, FL. The Seminar is being held in-person this year! Don't miss this opportunity to learn, share and network with seasoned legal and pharmaceutical professionals.  Attendees will have the opportunity to earn up to 15 hours of ACPE and CLE continuing education credits.  We look forward to having you join us in November!
More Episodes
In this episode of Post-Scrip, Henry introduces Jenni Wai, RPh. , MBA, Josh Bolin and Christopher R. Smith, JD, LLM. They discuss the upcoming "Regulatory, Industry and Legal Perspectives on the Future of the DSCSA".This presentation will provide an update on the final stages of implementation of...
Published 10/16/24
In this episode of Post-Scrip, Henry introduces Marty Allain, JD. They discuss the upcoming "How Drug Manufacturer Restrictions and Recent Court Decisions are Re-Shaping 340B Drug Distribution and Delivery Models".Pharmaceutical manufacturers continue to restrict the delivery of 340B drug...
Published 10/09/24